INTRODUCTION
The generics industry is facing a period of unprecedented growth, with $82
billion worth of global blockbusters set to face US patent expiry by 2007. The
changing dynamics of the generics market are driving strategic evolution of
leading players, with portfolio management, geographic expansion and alliance
networks determining success and failure. Datamonitor's analysis provides you
with the insight needed to understand the changing dynamics within the global
generics market to 2007.
SCOPE OF THIS REPORT
Benchmarking of leading players in the generics market by 2001 sales, profits
and R&D spend and by forecast generic sales between 2002 and 2007
In-depth analysis of portfolio management, geographical expansion and
partnership strategies and assessment of winners and losers
Full profiles of 10 of the leading generics companies- Alpharma, Andrx, Barr,
IVAX, KV Pharmaceuticals, Mylan, Ranbaxy, SICOR, Teva and Watson
One, three and six year forecasts for key products and total ethical sales for
10 generics companies, benchmarked against analyst consensus estimates
REPORT HIGHLIGHTS
The global generics market is forecast to significantly outperform the
branded sector in terms of sales growth between 2002 and 2007. While Teva will
maintain its lead at the head of the generics market, the chasing pack will see
changing fortunes as the boom and bust of paragraph IV filings take their toll.
Europe is set to outperform the US in terms of overall growth and companies
capitalizing on expanding opportunities in Southern Europe will see their
efforts rewarded by 2007.
Rising competition from Indian and Eastern European low cost providers will
augment the pressure on margins, forcing Western players to add value through
specialty generics and supergenerics.
KEY REASONS TO BUY THIS REORT
Benchmark your strategy against key rivals in the generics sector
Assess the timescale and impact of biogenerics on your business
Understand the drivers of growth in the major generics markets and their impact
on the branded sector
Realize the benefits and limitations of alliance networks with generics
companies
Effectively implement portfolio management strategies to maximize profit return
View Cart
